Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Clinical Neuropharmacology
|
January 1, 1992
Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results
S Bouquet, S Vandel, G Bertschy, et al.
Pharmacopsychiatry
|
December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype
E Haffen, P Vandel, F Broly, et al.
Therapie
|
January 1, 1997
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin
P Vandel, B Bonin, G Bertschy, et al.
L'Encephale
|
June 1, 1997
[Indications for electroconvulsive therapy]
J Boiteux, L Roubaud, N Gandelet, et al.
Therapeutic Drug Monitoring
|
December 29, 2000
Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation
M Gex-Fabry, E Haffen, G Paintaud, et al.
Pharmacological Research
|
June 1, 1995
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
S Vandel, G Bertschy, P Baumann, et al.
L'Encephale
|
May 1, 1996
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration]
B Bonin, G Bertschy, P Baumann, et al.
Neuropsychobiology
|
January 1, 1992
Tricyclic antidepressant plasma levels after fluoxetine addition
S Vandel, G Bertschy, B Bonin, et al.
Therapie
|
January 1, 1995
[Undesirable effects of drugs. Epidemiologic study at a psychiatric service of a university hospital]
P Vandel, P Bizouard, S Vandel, et al.
European Journal of Clinical Pharmacology
|
January 19, 2000
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
P Vandel, E Haffen, S Vandel, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Clinical Neuropharmacology
|
January 1, 1992
Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results
S Bouquet, S Vandel, G Bertschy, et al.
Pharmacopsychiatry
|
December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype
E Haffen, P Vandel, F Broly, et al.
Therapie
|
January 1, 1997
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin
P Vandel, B Bonin, G Bertschy, et al.
L'Encephale
|
June 1, 1997
[Indications for electroconvulsive therapy]
J Boiteux, L Roubaud, N Gandelet, et al.
Therapeutic Drug Monitoring
|
December 29, 2000
Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation
M Gex-Fabry, E Haffen, G Paintaud, et al.
Pharmacological Research
|
June 1, 1995
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
S Vandel, G Bertschy, P Baumann, et al.
L'Encephale
|
May 1, 1996
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration]
B Bonin, G Bertschy, P Baumann, et al.
Neuropsychobiology
|
January 1, 1992
Tricyclic antidepressant plasma levels after fluoxetine addition
S Vandel, G Bertschy, B Bonin, et al.
Therapie
|
January 1, 1995
[Undesirable effects of drugs. Epidemiologic study at a psychiatric service of a university hospital]
P Vandel, P Bizouard, S Vandel, et al.
European Journal of Clinical Pharmacology
|
January 19, 2000
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
P Vandel, E Haffen, S Vandel, et al.
Page
of 6